Outcomes of type 2 diabetes mellitus patients with heart disease on empagliflozin in comparison with other anti-diabetic drugs: An institutional perspective

Outcomes of type 2 diabetes mellitus patients with heart disease on empagliflozin in comparison with other anti-diabetic drugs: An institutional perspective

Bibliographic Details
Main Authors:	B. Aniketh Vijay, T. Rajesh, Devu Pavithran, Sreya Pushpan
Format:	Article
Language:	English
Published:	Elsevier 2017-11-01
Series:	Indian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483217305977

Similar Items

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
by: Hershon KS
Published: (2016-05-01)

Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
by: Vladimir V. Salukhov, et al.
Published: (2016-12-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
by: Andrew Ahmann
Published: (2015-11-01)

Diabetic Ketoacidosis in a Patient with Type 1 Diabetes Mellitus Treated with Low Insulin in Combination with Empagliflozin
by: Josá G. Jiménez-Montero, MD, FACE, et al.
Published: (2018-11-01)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
by: Kosuke Mozawa, et al.
Published: (2021-10-01)

A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus
by: Aktas, G., et al.
Published: (2022)

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
by: Sachiko Hattori
Published: (2018-12-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
by: Odette S. Reifsnider, et al.
Published: (2020-12-01)

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
by: EMPA-REG OUTCOME Investigators, et al.
Published: (2018)

Effect of Empagliflozin on Cardiac Function, Adiposity and Diffuse Fibrosis in Patients with Type 2 Diabetic Mellitus
by: Jung-Chi Hsu, et al.
Published: (2019)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
by: Mojca Lunder, et al.
Published: (2018-12-01)

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
by: Satoshi Oka, et al.
Published: (2021-04-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
by: Frank Gao, et al.
Published: (2020-04-01)

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
by: EMPA-REG OUTCOME Investigators, et al.
Published: (2016)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
by: Shubrook JH, et al.
Published: (2015-10-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
by: Oriol Iborra-Egea, MSc, et al.
Published: (2019-11-01)

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
by: Gretchen M. Ray, et al.
Published: (2019-05-01)

Evaluation of the Effect of Empagliflozin Therapy on T Helper 22 Cell-Related Factors in Patients with Type 2 Diabetes Mellitus
by: Hamid Moghimi, et al.
Published: (2021-03-01)

Renal effects and nephroprotection induced by SGLT2 inhibitor Empagliflozin in patients with Diabetes Mellitus: a literature review
by: Luis E. Morales-Buenrostro, et al.
Published: (2017-01-01)

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-08-01)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016-04-01)

The role of empagliflozin in the management of type 2 diabetes by patient profile
by: Hedrington MS, et al.
Published: (2015-05-01)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial
by: EMPA-REG OUTCOME Trial, et al.
Published: (2016)

Possible mechanisms for oxidative damage in diabetes mellitus and of some anti-diabetes drugs
by: Ou, Peimian
Published: (1996)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
by: Jordan Sexe, et al.
Published: (2020-01-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
by: Thomas A Zelniker, et al.
Published: (2019-01-01)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
by: Men P, et al.
Published: (2020-08-01)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
by: Agnes Bosch, et al.
Published: (2019-03-01)

Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
by: Concetta Irace, et al.
Published: (2018-04-01)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
by: Rafael de laEspriella, et al.
Published: (2020-12-01)

Heart pathology in diabetes mellitus
by: A. A. Arakeljantz, et al.
Published: (2004-02-01)

Diabetes Mellitus and Heart Failure
by: Filippos Triposkiadis, et al.
Published: (2021-08-01)

Empagliflozin: Novel antidiabetes and pro-cardiac drug
by: Monish S Raut, et al.
Published: (2017-01-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Cannot write session to /tmp/vufind_sessions/sess_cktsb1d7feqgj7vdertah2s6v3